PLATINUM DERIVATIVES AND CANCER TREATMENTS

Abstract: Derivatives of platinum group metals, particularly platinum itself, wherein the metal is linked to one or more pharmaceutically acceptable steroid, fatty acid or other lipophilic residues aiding transport of the metal across cell membranes in the body, particularly fatty acid amine or fatty acid amide groups RCH₂NH- or where R is a hydrocarbon group, suitably of 10 to 30 carbon atoms. The derivatives are useful in the treatment of cancer.

Description: FIELD OF THE INVENTION The invention relates to heavy metal derivatives and their use in the treatment of various carcinomas. GENERAL BACKGROUND Platinum diamine dichloride (variously, cis-platinum, cis-platin, platamine, etc.) has been used as a treatment for certain carcinomas (mainly prostatic) for several years, but suffers from the drawback of requiring large dosages which induce unpleasant side-effects (hair loss, nausea, anaemia, etc.). The compound is believed to work by forming stable complexes with DNA in cell nuclei. This prevents both transcription of the DNA, thus blocking protein synthesis, and replication of the DNA thus inhibiting mitosis. The treatment therefore is not specific for cancer cells only, but also affects cells which normally multiply (bone marrow, skin, gut epithelium, etc.), or synthesise proteins (e.g. liver). The apparent main reason for the high dosages required is the hydrophilic (lipophobic) nature of the compound, and thus the difficulty of its passage through the mainly lipid environment of cell membranes. In the prior art, further, EP-A-0,193,936 discloses as anti-cancer agents platinum (II) complexes PtR₁R₂(R₃)₂ where R₅ is a saturated or unsaturated higher fatty acid which is e.g. linoleic acid and R₁ and R₂ are ammines optionally substituted with an organic substituent which is e.g. a C1 to C5 alkyl group. Certain unsaturated fatty acids have been shown to have much higher levels of toxicity towards cancer cells than normal cells. The mechanism for this is not clear, but is thought to relate to an impaired capability of cancer cells to metabolise fatty acids normally, and thus an inability to respond properly to exogenous dosage with such fatty acids. The position of the unsaturations in the hydrocarbon chain does not appear to be critical for the production of cytotoxic effects, with the proviso that such unsaturations are desirably methylene-interrupted and that desirably the first unsaturation is in the n-3, n-6, or n-9 position. The number of unsaturations does appear to matter however, with toxicity increasing with number of unsaturations. In general the configuration (cis or trans) of the unsaturations does not have much effect on cytotoxicity. Such fatty acids are obviously highly lipophilic and hydrophobic, thus the generation in vivo of levels high enough to facilitate cytotoxic effects is difficult. PREFERRED FATTY ACIDS Preferred unsaturated fatty acids are those of the natural n-6 and n-3 essential fatty acid series as undesired side effects are not to be expected from them. The two series are given below, showing the metabolic pathways. The acids, which naturally are of the all-cis configuration, are systematically named as derivatives of the corresponding octadecanoic, eicosanoic or docosanoic acids e.g. delta 9,12-octadecadienoic acid or delta 4,7,10,13,16,19-docosahexaenoic acid, but numerical designation such as, correspondingly, 18:2 n-6 or 22:6 n-3 is convenient. Initials, for example DHA for 22:6 n-3 ( d ocosa h exaenoic a cid) are also used but do not serve when n-3 and n-6 acids of the same chain length and degree of unsaturation exist (e.g. 22:5 n-6 and 22:5 n-3). Trivial names in more or less common use in the n-6 series are as shown. Of the n-3 series only 18:3 n- 3 has a commonly used trivial name, alpha-linolenic acid. It was characterised earlier than gamma-linolenic acid and reference in the literature simply to linolenic acid, especially in the earlier literature, is to the alpha-acid. The invention provides derivatives of platinum group metals (Ru, Rh, Pd, Os, Ir, Pt), particularly platinum itself, wherein the metal is linked to one or more pharmaceutically acceptable fatty acid amine or fatty acid amide groups wherein R represents the hydrocarbon chain of an unsaturated essential fatty acid of the natural n-6 or n-3 series. The invention also relates to the preparation of a composition for treating cancer wherein there is used such a platinum group metal derivative in a pharmaceutically acceptable diluent of carrier, for administration in amounts effective to inhibit cancer cell multiplication. Desirably the amounts are selected from those effective to inhibit the multiplication of cancer cells when tested in vitro, and desirably dosage units are used suited to administration of 100 microg to 10 g of the derivatives daily. Use of the derivatives of the invention makes the platinum or other metal much more lipophilic and thus improves its ability to pass through cell membranes. It is therefore possible to block protein synthesis and cell division with much smaller dosages than with the platinum diamine dichloride alone. Such effects do not require the hydrocarbon chain to be unsaturated. The advantage of using unsaturated fatty acids is that they in themselves also cause cytotoxicity, and thus lower dosages will be cytotoxic by a combination of the DNA blocking effect of the platinum compound and membrane perturbation or other effects of the fatty acids. Moreover, as the fatty acid effect is particular to the cancer cells, the combination may be expected to be lethal to cancer cells alone. SYNTHESES Two methods of preparing fatty acid amides (R = fatty acid "tail") have been used:- A) 10g fatty acid + 2ml thionyl chloride + 50 ml chloroform + 3 drops dimethyl formamide. Reflux for 100 minutes to give acyl chloride. Distil off solvent. Cool to 0°C. Add 20ml NH₃. Stand 20 mins. + 30 ml CHCl₃. Stand 1 hour. Suction filter. Wash with CHCl₃. Rotary evaporate. Recrystallise from ethanol. B) 10g fatty acid in 100ml methanol. Bubble freshly generated HCl for 15 mins. Stand 5 mins. Rotary evaporate. Wash with methanol at 0°C. Redissolve 0.5g product in 30ml CHCl₃ on ice. Add 7ml NH₃. Stand 30 mins. Rotary evaporate. Recrystallise from ethanol. Reduction and platinum reaction steps are as follows. 1) Dissolve 0.5g fatty acid amide in 30ml THF and reduce with 0.17g LiAlH₄. Reflux at 75°C for 4 hours. Suction filter. Wash with ether. Rotary evaporate to give the "fatty acid amine" product. 2) 100mg PtCl₄ in 10ml H₂O + 2.4ml 0.1M HCl. Add 0.2g amine in 15ml CHCl₃. Mix. Stir overnight. Remove CHCl₃ layer. Rotary evaporate. Recrystallise the platinum derivative. The above has been performed with linoleic acid as substrate, however the same process can be directly applied to the other fatty acids intended as substrates. PURIFICATION The material has been purified by thin layer chromatography (TLC) and 3 fractions found. Molecular mass studies indicate these are platinum trichloro (linoleoylamine (fraction [1]), platinum dichloro dilinoleoylamine (fraction [2]), and platinum mono chlorotrilinoleoylamine (fraction [3]), approximately 2:1:1 mono- to di- to tri- linoleoylamine. All 3 compounds have been further purified by repeat TLC. (Note: "linoleoyl" in this context is RCH₂- derived by reduction of linoleoyl proper IN VITRO ASSESSMENT Both the crude mixture and the purified fractions have been assessed in regard to their cytotoxicity. The cell lines used have been derived from a wide range of carcinomas as well as benign, normal and primary cultures. 1. Carcinoma cell lines. The crude mixture has on molar basis proven to be more effective than either platinum diamine dichloride or the parent fatty acid (linoleic acid). The fractions [2] and [3] produced cytotoxic effects but were not as potent as the crude mixture. Fraction [1] was slightly more potent (+/-10%) than the crude mixture. When a mouse myeloma (SP210) line was used the crude mixture was 3 times as cytotoxic as platinum dichloride, similarly with a malignant fibroblast (3T6D) it was 4 times as potent, with a neuroblastomaglioma hybrid (NG108-15) 5 times, and with a human hepatoma twice as potent. 2. Benign cell lines. Two benign cell lines (3T3 and 3T6), both fibroblast derived, have been used. Both fraction [1] and the crude mixture proved about twice as potent as platinum diamine dichloride. 3. Normal cell lines. Normal skin fibroblasts, liver cells, and brain cells maintained in culture exhibited similar susceptibility to fraction [1], crude mixture, or platinum diamine dichloride induced cytotoxicity. 4. Primary culture. A primary culture of a human ovarian carcinoma was 3 times more susceptible to cytotoxicity induced by the crude mixture and fraction [1] than the platinum diamine dichloride. DOSAGES The dosages required in microg/ml culture medium in vitro to produce 50% cell death (LD50) for the 3 fractions, the crude mixture, the parent fatty acid, and platinum diamine dichloride, for all the cell lines used, are shown in Table 1. IN VIVO ASSESSMENTS Promising preliminary indications have been gained using carcinomas transplanted into nude mice.

Claims: Derivatives of platinum group metals (Ru, Rh, Pd, Os, Ir, Pt), particularly platinum itself, wherein the metal is linked to one or more pharmaceutically acceptable fatty acid amine or fatty acid amide groups wherein R represents the hydrocarbon chain of an unsaturated essential fatty acid of the natural n-6 or n-3 series. Preparation of composition for treating cancer wherein there is used a heavy metal derivative according to claim 1 in a pharmaceutically acceptable diluent or carrier, for administration in amounts effective to inhibit cancer cell multiplication. Preparation according to claim 2 wherein the amounts are selected from those effective to inhibit the multiplication of cancer cells when tested in vitro, and desirably dosage units are used suited to administration of 100 microg to 10 g of the derivatives daily. CLAIMS for the contracting state: AT. Method of preparing new derivatives of platinum group metals (Ru, Rh, Pd, Os, Ir, Pt), particularly of platinum, wherein the metal is linked to at least one fatty acid amine of general formula or to at least one fatty acid amide of general formula wherein R represents the hydrocarbon chain of an unsaturated essential fatty acid of the natural n-6 or n-3 series, characterised in that a fatty acid amine of general formula or a fatty acid amide of general formula wherein R is defined as above, is reacted with a salt of a platinum group metal, particularly platinum. Method according to claim 1, characterised in that a chloride of a platinum group metal, particularly platinum is reacted. Method according to claim 1 or 2, characterised in that the fatty acid amide of general formula wherein R is defined as in claim 1, is prepared by reacting a fatty acid of general formula wherein R is defined as in claim 1, with a thionyl halide or a hydrogen halide to form the corresponding fatty acid halide, that the fatty acid halide thus obtained is reacted with ammonia to form the corresponding fatty acid amide and that the fatty acid amide thus obtained is reacted according to claim 1 to form a metal derivative. Method according to any of claims 1 to 3, characterised in that the fatty acid amide obtained according to claim 3 is reduced to form the corresponding fatty acid amine and that the fatty acid amine thus obtained is reacted according to claim 1 to form a metal derivative. Method according to claim 4, characterised in that the reduction is made with LiAlH₄ in tetrahydrofuran. Method according to any of claims 1 to 5, characterised in that the metal salt dissolved in hydrochloric acid is reacted with the fatty acid amide or fatty acid amine dissolved in chloroform. CLAIMS for the contracting state: ES Method of preparing derivatives of platinum group metals (Ru, Rh, Pd, Os, Ir, Pt), particularly of platinum, characterised in that the metal is linked to at least one fatty acid amine of general formula or to at least one fatty acid amide of general formula wherein R represents the hydrocarbon chain of an unsaturated essential fatty acid of the natural n-6 or n-3 series, by reacting a fatty acid amine of general formula or a fatty acid amide of general formula wherein R is defined as above, with a salt of a platinum group metal, particularly platinum. Method according to claim 1, characterised in that a chloride of a platinum group metal, particularly platinum is reacted. Method according to claim 1 or 2, characterised in that the fatty acid amide of general formula wherein R is defined as in claim 1, is prepared by reacting a fatty acid of general formula wherein R is defined as in claim 1, with a thionyl halide or a hydrogen halide to form the corresponding fatty acid halide, that the fatty acid halide thus obtained is reacted with ammonia to form the corresponding fatty acid amide and that the fatty acid amide thus obtained is reacted according to claim 1 to form a metal derivative. Method according to any of claims 1 to 3, characterised in that the fatty acid amide obtained according to claim 3 is reduced to form the corresponding fatty acid amine and that the fatty acid amine thus obtained is reacted according to claim 1 to form a metal derivative. Method according to claim 4, characterised in that the reduction is made with LiAlH₄ in tetrahydrofuran. Method according to any of claims 1 to 5, characterised in that the metal salt dissolved in diluted hydrochloric acid is reacted with the fatty acid amide or fatty acid amine dissolved in chloroform. CLAIMS for the contracting state: GR. Derivatives of platinum group metals (Ru, Rh, Pd, Os, Ir, Pt), particularly platinum itself, wherein the metal is linked to one or more pharmaceutically acceptable fatty acid amine or fatty acid amide groups wherein R represents the hydrocarbon chain of an unsaturated essential fatty acid of the natural n-6 or n-3 series. Preparation of composition for treating cancer wherein there is used a heavy metal derivative according to claim 1 in a pharmaceutically acceptable diluent or carrier.

Inventors: DAVIDSON, BRUCE CLEMENT
Applicants: EFAMOL HOLDINGS PLC
Application year: 1987
Main classification: C07F15
IPC codes: C07J51, C07F15, A61K31, C07J9, A61P35